PF-Atlas › Clinical Trials › NCT01362231

A Study to Evaluate the Safety and Efficacy of GS-6624 in Patients With Idiopathic Pulmonary Fibrosis

GS-6624 · Phase 1

Registry ID

NCT01362231

Phase

Phase 1

Status

Completed

Drug / intervention

GS-6624

Sponsor

Gilead Sciences

Start

2010-12

About this trial

GS-6624 is evaluated in NCT01362231, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Gilead Sciences. Current status: Completed.

View NCT01362231 on ClinicalTrials.gov →

Explore related

All GS-6624 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01362231 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.